Crown Bioscience is Largest Commercial Provider of Small Cell Lung Cancer PDX Models
(Santa Clara, Calif., Nov. 3, 2015) — Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology and metabolic disease research, is proud to host the world’s largest commercially available portfolio of small cell lung cancer (SCLC) PDX models.
“Lung cancer is the most common type of cancer worldwide,” said Jean-Pierre Wery, Ph.D., president of Crown Bioscience. “Although small cell lung cancer has been responsive to both chemotherapy and radiotherapy treatments, patients often relapse. Better treatments are needed. Our 70 individual SCLC PDX models capture the diversity of the patient populations, include primary and metastatic tumors, and offer the most relevant pre-clinical models for development of drugs to treat SCLC. ”
Because SCLC is commonly found in both lungs, surgery alone is rarely a viable solution, and chemotherapy-based approaches have not resulted in major advances in its treatment in more than 20 years. Working at the forefront of SCLC research, Crown Bioscience developed the HuPrime® and PDXact™ Jumpstart collections of SCLC models, which are the most comprehensive collection of commercially available preclinical models.
Most of the 70 models have RNA sequence data, and more than half have in vivo standard of care data. Scientists can study varying tumor types by working with a diversified selection of both sensitive and resistant models. Subsets of the models show initial responses followed by relapses, mirroring responses observed in clinics. The variety of lesions available result in models that represent the diversity of the patient population.
Researchers are invited to learn more about the models and speak with Crown Bioscience experts at the company’s translational oncology symposium at the Boston Museum of Science Nov. 4, 2015, or at Booth 500 at the AACR-NCI-EORTC International Conference in Boston, Nov. 5–9, 2015. More information is also available at www.crownbio.com.
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development service company providing translational platforms to advance oncology and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, please visit www.crownbio.com.